Marshall Clinical Research Center (MCRC) was one of the centers from around the world honored by the opportunity to work with Pfizer’s clinical research team on the Matisse Study. The Matisse study was designed for the prevention of Respiratory Syncytial Virus in infants through active immunization of pregnant individuals 32-36 week of gestational age. Dr. Keblawi was the principal investigator that led the charge at Marshall. Under his supervision MCRC enrolled 8 participants. The study involved four visits for the mother and six visits for the baby and lasted a total of 12 to 24 months, depending on how long the mother wanted to participate in the study. The study was active from November 2020 to August 2023. During the duration of the study, MCRC study coordinators spent countless hours working with the PI and participants to ensure proper conduction of the clinical trial. In August 2023, Pfizer announced the U.S. FDA Approval of the ABRYSVO Vaccination and within days had European approval as well.
